Detection of high-risk HPV (16, 18, 33) in situ cancer of the cervix by PCR technique

Objective: The purpose of this study was to collect data about the incidence of high-risk HPV (16, 18, 33) types in in situ cervical cancers, and to evaluate the reliability of the morphological signs of HPV infection by comparing the presence of these signs to the PCR-proven HPV virus infection.

Methods: Fifty patients who underwent conisation at the Department of Obstetrics and Gynecology of Semmelweis University, Budapest, Hungary because of in situ cervical cancer were examined retrospectively for the presence of HPV infection by the PCR technique. The direct and indirect morphological signs of HPV infection identified in the histological and cytological samples were compared to the actual results of virus DNA amplification by PCR in the identical histological sections. The evaluation of the cytological smears and the histological sections was accomplished independently by two different pathologists.

Results: E6 open reading frame of HPV 16, 18 or 33 was detected by PCR in 56% (28 cases) of the histological sections of the 50 examined patients with in situ cancer. In 92% (26 patients) of the 28 HPV positive patients one HPV type was detected, while in one of the remaining two cases two HPV types (16/33), or all three types could be detected. The direct morphological signs for HPV infection proved to be 75% sensitive and 50% specific when compared to the results of PCR. Their predictive value for HPV infection was 65%. For the indirect HPV signs the sensitivity was 64% and specificity 31%. The predictive value, prognosticating the presence of HPV 16, 18, 33 infection was 54% in the same sections. Using significance analysis no significant relationship (p = 0.7728) could be detected between the positivity of indirect signs and the presence of HPV 16, 18, 33 infection, while in case of direct signs the relationship was almost significant (p = 0.0675). The joint testing of the direct and indirect signs did not improve the results (p = 0.1338). During the review of the cytological smears the specificity of the cytology in predicting true HPV infections was found to be 68% and sensitivity was 20%. The predictive value was only 50%. A significance analysis was not accomplished by this diagnostic method because of the missing data (see text).

Conclusion: The method of Nawa et al. seems to be a reliable approach for the detection of HPV DNA in paraffin-embedded material. The three main types of HPV (16, 18, 33) are probably represented in lower percentages in CIN III in Hungary, but a larger survey is needed to obtain reliable data. The direct and indirect morphological signs of HPV infection failed to show a significant relationship with the PCR proven presence of HPV 16, 18, 33.

Cervix; Colposcopy; Cytology; Histology; Genital infections; Mycoplasma; HPV; HSY; Adenovirus; Chlamydia trachomatis

[1] Zur Hausen H.: "Human pap仆lomaviruses in the pathogenesis of anogenital cancer". Virology, 199 I, 184, 9.

[2] Stoller H. M.: "Human papillomaviruses and cervical neoplasia: A model for carcinogenesis". Int. J. Gynec. Pathol., 2000, 19, 16.

[3] Lombart I., Vincent-Salomon A., Validire P., Zafrani B., dela Rochefordiere A., Clough K. et al.:''Human papillomavirus genotype as a major determinant of the course of cervical cancer" J. Clin. Oncol. 1998, 16(8), 2613.

[4] Ylitano N., Josefsson A., Melbye M., Sorensen P.. F risch M., Anderson P. K. et al.: "A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ". Cancer Res. 2000, 60(21), 6027.

[5] Deacon J. M., Evans C. D., Yule R., Desai M., Binns W., Taylor C., Petro J.: "Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a casecontrol study nested within the Manchester cohort". Br. J. Cancer, 2000, 83(11), 1565.

[6] Carozzi F., Ronco G., Confortini M., Noferini D., Maddau C., Ciatto S., Segnan N.: "Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing". 81: J. Cancer, 2000, 83(11), 1462.

[7] Rozendaal L., Westarga J., van der Linder J. C、Walboomers J M., Voorhorst F. J., Risse E. K. et al.: "PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes". J. Clin. Pathol., 2000, 53(8), 606.

[8] "Cervical Cancer", NIH Consensus Statement, 1996, 14(1), 1.

[9] Burger R. A., Monk B. J., Kurosaki T., Anton-Culver H., Vasilcv S. A., Berman M. L., Wilczynski S. P.: "Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer". J. Nat. Cane. Inst., 1996, 88(19), 1361.

[10] Pillai M. R., Lakshmi S., Sreekala S., Devi T. G., Jayaprakash P G., Rajalakshmi T. N. et al.: "High-risk human papillomavirus infection and E6 protein expression in lesions of the uterine cervix". Pathobiology, 1998, 66(5), 240.

[11] Holub Z.,L ukac J.,C hvalova M.,B rozkova H.,N ovakova M., Poustkova M.: "Evaluation of the role of the HPV test in routin clinical practice: prospective study". Ceska Gynecol., 1999, 64(4), 238.

[12] Ostor A. G.: "Natural history of cervical intraepithelial neoplasia a critical review". Int. J. Clinical. Pathol., 1993,12, 186.

[13] Arends M. J., Wyllie A. H., Bird C. C.: "Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16". Br. J. Cancer, 1995, 72(3), 646.

[14] Quan M. B., Moy R. L.: "The role of human papillomavirus in carcinoma". J. Am. Acad. Dermatol., 1991, 25, 698.

[15] van den Brule A. J. C., Snijders P. F. J., Meijer C. J. L. M. et al. "PCR based detection of genital HPV genotypes: An update and future perspectives". Papillomavirus Report., 1993, 4, 95.

[16] Tseng C. J., Pao C. C., Lin J. D., Soong Y. K., Hong J. H., Hsueh S.: "Detection of human papillomavirus type 16 and 18 mRNA in peripheral blood of advanced cervical cancer patient and its association with prognosis". J. Clin. Oncol., 1999, 17(5), 1391.

[17] Nawa A.,N ishiyama Y.,K ikkawa F.,K awai M.,M ano H.. Goto S et al.: "Detection of human papillomaviruses from histologically normal lymph nodes of Japanese cervical cancer patients by nested polymerase cha i merase chain-reaction assay". Int. J. Cancer, 1993, 53, 932.

[18] Dixon W. J.: "BMDP Statistical Software Manual". University of California, Berkeley, 1992.

[19] Tseng C-J., Tseng L-H., Lai C-H., Soong, Y-K., Chia-Cpao S. H.: "Identification of human papillomavirus types 16 and 18 deoxyribonucleic acid sequences in bulky cervical cancer after chemotherapy". Am. J. Obstet. Gynecol., 1997, 176, 865.

[20] Butler D., Collins C., Mabruk M., Walsh C. B., Leader M. B., Kay E. W.: "Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features". J. Pathol., 2000, 192, 502.

[21] Josefsson A. M., Magnusson P. K. E., Yilitalo N., Sorensen P., Qwarfort-Tubbing P., Andersen P. K. et al.: "Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study". Lancet, 2000, 355, 2189.

[22] Klaes R., Woerner S.M., Ridder R., Wentzensen N., Duerst M., Schneider A. et al.: "Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogen". Cancer Research, 1999, 59, 6132.

[23] de Roda Husman A. M., Walboomers J. M., Meijer C. J., Risse E K., Schipper M. E., Helmerhorst T. M. et al.: "Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction". Int. J. Cancer, 1994, 56(6), 802

[24] Schneider A., Hoyer H., Lotz B., Leinstritz S., Ktihne-Heid R., Nindl I. et al.: "Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy". Int. J. Cancer (Pred. Oneal.), 2000, 89, 529.

[25] Sawaya G. F., Grimes D. A.: "New technologies in cervical cytology screening: a word of caution". Obs tet Gynecol., 1999, 94(2), 307.

[26] Tachezy R., Hamsikova E., Hajek T., Mikyskova I., Smahel M., Van Ranst M. et al.: "Human papillomaviris genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles". J. Med. Viro/., 1999, 58(4), 378.